Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans
Authors' conclusion
Sequential Romo6M + Dmab treatment demonstrates comparable efficacy to Romo12M treatment in improving BMD, with fewer injections and potential cost benefits.
Study context
- Population
- Treatment-naïve Korean patients with osteoporosis
- Participants
- 156 patients
- Exposure
- 6-month romosozumab followed by denosumab vs 12-month romosozumab
- Romo6M + Dmabn = 41
- Romo12Mn = 115reference
- Outcome
- LS-BMD percentage change
- Follow-up
- 12 months
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
Romo6M + Dmab
16.9%
least-squares mean · SE 4.6%
Romo12M
16.9%
least-squares mean · SE 3.4%
P = 0.936
Observational data: associations, not effects.
Further findings
Least-squares mean
| Outcome | Romo6M + Dmab | Romo12M | P value |
|---|---|---|---|
| TH-BMD percentage change · 12 monthsNot significant | 4.6% (SE 3.9%) | 4.4% (SE 2.9%) | P = 0.911 |
| FN-BMD percentage change · 12 monthsNot significant | 3.2% (SE 3.9%) | 4.2% (SE 3.1%) | P = 0.357 |
- Bone turnover markers (BTMs) · 12 months · higher in Romo12M
- P < 0.001
- Trabecular bone score (TBS) · 12 months · not significant
- P = 0.989
BTMs · 12 months
- Baseline, 1-month and 6-month BTM levels comparable between groups
TBS · 12 months
- TBS increased significantly only in Romo12M
Bone mineral density (BMD) gains · 24 months
- BMD gains at 24 months remained similar
- Subset of 96 patients (Romo6M + Dmab: n = 27; Romo12M: n = 69) after 12 months of additional Dmab
Original publication
Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans. Eur J Endocrinol. Published 17 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →